For instance, IL-2-based immunotherapy has demonstrated increased efficacy in malignancies such as melanoma and renal cell carcinoma (RCC), attributed to their higher expression of IL-2R ([7, 8]). This evidence concerns the gene IL2RA and renal cell carcinoma.